Skip to content
DataLookout
Menu

NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

StatusRecruiting
PhasePhase 3
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 449 → 469 locations
  2. Minor Study sites: 449 to 447
  3. Minor Trial sites expanded: 431 → 449 locations
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 2 of 15 entries
  4. Minor Trial sites expanded: 425 → 431 locationsv10
  5. Minor Trial sites expanded: 402 → 425 locationsv9
  6. Minor Trial sites expanded: 305 → 402 locationsv8
  7. Minor Trial sites expanded: 280 → 305 locationsv7
  8. Minor Trial sites expanded: 253 → 280 locationsv6
  9. Minor Study sites: 218 to 253v5
  10. Notable Primary endpoints: 2 to 1
    • Study sites: 89 to 218
    • Eligibility criteria shortened, about 44 words
    • Secondary endpoints: 14 to 15
    v4
  11. Minor Study sites: 6 to 89v3
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 6
    • Start date changed from estimate of Aug 22, 2025 to Sep 29, 2025
    • Eligibility criteria expanded, about 10 words
    v2
  13. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Survival
Timeframe: Approximately 5 years

Secondary (15)

Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
Objective Response Rate as assessed by BICR
Progression Free Survival as assessed by Investigator
Objective Response Rate (ORR) as assessed by Investigator
Duration of Response as assessed by BICR
Show 10 moreShow less
Duration of Response as assessed by Investigator
Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation
Mean scores and Change from baseline in the global health status/quality of life (QoL) score on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Mean scores and Change from baseline in physical functioning and role functioning scores on the EORTC QLQ-C30
Mean scores and Change from Baseline in dyspnea, cough, and chest pain scores on the EORTC Quality of Life Cancer Questionnaire - Lung Cancer 13 QLQ-LC13
Time to definitive deterioration (TTdD) in in the global health status/QoL score on the EORTC QLQ-C30
TTdD in physical functioning and role functioning scores on the EORTC QLQ-C30
TTdD in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13
Pharmacokinetics (PK): Plasma concentration of PF-08046054 and and its components
Incidence of Anti-Drug Antibody (ADA)

Arms and interventions

PF-08046054 monotherapyExperimental

PF-08046054 monotherapy

Docetaxel monotherapyActive comparator

Docetaxel monotherapy

Drugs: PF-08046054, Docetaxel monotherapy

Sites

469 sites in 29 countries

United States 262, China 24, Japan 19, Germany 15, Spain 14, France 11, Italy 11, South Korea 11, Canada 10, Greece 8, Argentina 7, Czechia 6, India 6, Israel 6, Taiwan 6, Belgium 5, Brazil 5, Denmark 5, Australia 4, Bulgaria 4, Finland 4, Mexico 4, Netherlands 4, Poland 4, Slovakia 4, United Kingdom 4, Sweden 3, South Africa 2, Puerto Rico 1